Purpose: The aim of this study is to evaluate the efficacy and the safety of additional 4-week chemotherapy with capecitabine during the resting periods after a 6-week neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer.
Methods: Radiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m(2) twice daily for 10 weeks. Surgery was performed 2-4 weeks following the completion of chemotherapy.
Results: Between January 2010 and September 2011, 44 patients were enrolled. Forty-three patients underwent surgery, and 41 patients completed the scheduled treatment. Pathologic complete remission (pCR) was noted in 9 patients (20.9%). T down-staging and N down-staging were observed in 32 patients (74.4%) and 33 patients (76.7%), respectively. Grade 3 to 5 toxicity was noted in 5 patients (11.4%). The pCR rate was similar with the pCR rates obtained after conventional NCRT at our institute and at other institutes.
Conclusion: This study showed that additional 4-week chemotherapy with capecitabine during the resting periods after 6-week NCRT was safe, but it was no more effective than conventional NCRT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837084 | PMC |
| http://dx.doi.org/10.3393/ac.2013.29.5.192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
BMC Cancer
January 2025
Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 PanjiayuanNanli, Chaoyang District, Beijing, 100021, China.
Anti-angiogenesis offers an important treatment strategy for metastatic breast cancer (MBC). Metronomic chemotherapy (MCT) provides antiangiogenic effects without increased toxicities, making it good partner for antiangiogenic therapy. We conducted the present retrospective study to evaluate the efficacy and safety of anlotinib plus MCT for HER2 negative MBC.
View Article and Find Full Text PDFValue of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial).
BMJ Open
January 2025
Colorectal Cancer Center, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Introduction: The standard of care for stage III colon cancer is 3 or 6 months of double-drug regimen chemotherapy following radical surgery. However, patients with positive circulating tumour DNA (ctDNA) exhibit a high risk of recurrence risk even if they receive standard adjuvant chemotherapy. The potential benefit of intensified adjuvant chemotherapy, oxaliplatin, irinotecan, leucovorin and fluoropyrimidine (FOLFOXIRI), for ctDNA-positive patients remains to be elucidated.
View Article and Find Full Text PDFMetronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-The Phase III MECCA Trial.
J Clin Oncol
January 2025
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Purpose: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.
Methods: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled.
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Anticancer Res
January 2025
Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
Article Synopsis
- A study explored salvage chemotherapy using capecitabine plus oxaliplatin (XELOX) for gastric cancer patients who couldn't tolerate or were resistant to cisplatin, but it was halted due to low patient enrollment.
- 12 patients participated, revealing a disease control rate of 90% and a response rate of 30%, with median progression-free survival of 4.2 months and overall survival of 7.1 months.
- Common severe side effects included fatigue and low potassium levels, but there were no treatment-related deaths, suggesting XELOX might be beneficial for these patients.
Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.
Anticancer Res
January 2025
Department of Integrated TCM & Western Medicine, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, P.R. China
Article Synopsis
- Colorectal cancer is the third most common cancer, and managing unresectable metastatic cases, especially those with MSS and BRAF V600E mutation, poses significant challenges for treatment.
- Two case reports illustrate the effectiveness of an alternating chemotherapy regimen (irinotecan and oxaliplatin along with capecitabine and bevacizumab) in two patients with MSS, BRAF V600E-mutated stage IV metastatic CRC, demonstrating a partial response and dropping carcinoembryonic antigen levels.
- The study suggests that this alternating regimen offers a promising treatment strategy with improved progression-free survival compared to standard first-line therapies, making it a potential first-line option for patients with this specific type of colorectal cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!